

Press Release

Capital increase successfully completed

- ♦ Capital increase of CHF 15 million successfully completed
- Potential for growth investments created
- ♦ Fiscal year 2021 the most successful in the company's history

Stetten, Switzerland, March 09th, **2022** - Exentis Group AG, provider of the world's unique 3D technology platform that enables mass production, has successfully started its 2022 fiscal year.

Exentis has successfully closed a growth financing round with subscription commitments totalling CHF 15 million at a share price of CHF 7.50. Approximately CHF 13 million has been drawn down and is available to Exentis for investments in core functions as well as for its further continuing international expansion. Exentis received considerable attention from institutional investors from all over Europe.

Klaus Radakovics, CFO: "The additional funds will enable us to further accelerate our profitable growth path. A particular focus will be the expansion into the American market. With the world's largest potential for additively manufactured industrial components in millions."

The demand for licences of the comprehensively patented Exentis technology, which is based on more than 3,400 patent claims, as well as for Exentis 3D production systems had already defined the fiscal year 2021. In spite of the restrictions imposed by Corona, there was increasing demand for 3D production systems for industrial applications as well as clean room applications for the mass production of active

pharmaceutical ingredients. As a result, Exentis was able to end the previous fiscal year as the most successful in the company's history. Once the financial audit has been completed, Exentis will present its annual financial results.

About Exentis

As a solution provider, Exentis has the only 3D technology platform worldwide that allows mass production. Industrialized Additive Manufacturing is universally applicable. For industrial or clean room applications. With free choice of materials, such as metals, ceramics, polymers, pharmaceutical or bioprinting products. 3D cold printing technology is sustainable and conserves materials as well as resources. The highly flexible 3D production technology combines rework-free component geometries with market-leading cost-benefit ratios. This allows customers to choose between producing millions of parts at Exentis or, as a member of the Exentis 3D Community, manufacturing in-house under license agreements when purchasing Exentis 3D development and production systems.

For further information please contact:

Exentis Group AG

Klaus Radakovics
Chief Financial Officer
+ 41 (0) 56 520 74 06
k.radakovics@exentis-group.com
www.exentis-group.com

Visit us also on YouTube "Exentis Group"